Novabay Pharmaceuticals Inc [AMEX: NBY] gained 48.92% or 0.24 points to close at $0.74 with a heavy trading volume of 145035168 shares.
The daily chart for NBY points out that the company has recorded -84.59% loss over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 272.22K shares, NBY reached to a volume of 145035168 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Novabay Pharmaceuticals Inc [NBY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NBY shares is $7.30 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NBY stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Ladenburg Thalmann have made an estimate for Novabay Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 18, 2019. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on July 06, 2018, representing the official price target for Novabay Pharmaceuticals Inc stock. Previously, the target price had yet another drop from $10 to $8, while Laidlaw kept a Buy rating on NBY stock.
The Average True Range (ATR) for Novabay Pharmaceuticals Inc is set at 0.09, with the Price to Sales ratio for NBY stock in the period of the last 12 months amounting to 0.30.
Trading performance analysis for NBY stock
Novabay Pharmaceuticals Inc [NBY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 55.82. With this latest performance, NBY shares gained by 35.80% in over the last four-week period, additionally sinking by -84.59% over the last 6 months – not to mention a drop of -95.22% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NBY stock in for the last two-week period is set at 61.79, with the RSI for the last a single of trading hit 79.29, and the three-weeks RSI is set at 48.87 for Novabay Pharmaceuticals Inc [NBY]. The present Moving Average for the last 50 days of trading for this stock 0.8309, while it was recorded at 0.5531 for the last single week of trading, and 3.7436 for the last 200 days.
Novabay Pharmaceuticals Inc [NBY]: A deeper dive into fundamental analysis
Novabay Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.43 and a Current Ratio set at 0.62.
An analysis of Institutional ownership at Novabay Pharmaceuticals Inc [NBY]
There are presently around $0.24%, or 0.24%% of NBY stock, in the hands of institutional investors.
